Recombinant Mouse Integral membrane protein DGCR2/IDD (Dgcr2)

What is the molecular structure and function of DGCR2/IDD protein?

DGCR2 is a membrane glycoprotein characterized by several distinct structural domains including a cysteine-rich repeat domain, a C-type lectin domain, and a transmembrane domain. The protein's structure shares homology with the mouse seizure-related gene SEZ-12 .

Functionally, DGCR2 acts as a cell adhesion molecule enriched in postsynaptic densities (PSDs). It contains a PDZ-interacting motif in its C-terminal region that mediates interaction with PSD-95, as demonstrated by co-immunoprecipitation studies. Deletion of the last three amino acid residues (∆TVV) prevents this interaction, confirming the specificity of this binding domain .

DGCR2 plays crucial roles in:

• Dendritic spine formation and development

• Glutamatergic synaptic transmission

• Synaptic plasticity through cell adhesion mechanisms

• Neural circuit formation and function

The protein functions through transcellular interactions, particularly with Neurexin1 (NRXN1), facilitated by its extracellular domain (ECD) .

How is DGCR2/IDD expressed during neurodevelopment?

DGCR2 expression increases progressively during neurodevelopment, with expression patterns that correlate with periods of active synaptogenesis. Studies have shown that DGCR2 is highly enriched in postsynaptic density fractions but not in presynaptic membrane fractions, confirming its postsynaptic localization .

Expression analysis across developmental stages shows:

• Increasing expression during early postnatal development

• Peak expression during periods of synaptic formation and maturation

• Sustained expression in adult brain tissue, particularly in regions rich in glutamatergic synapses

The developmental regulation of DGCR2 expression suggests its importance in establishing neural circuits during critical periods of brain development .

What genomic features characterize the DGCR2 gene?

The DGCR2 gene spans approximately 96kb of genomic DNA and comprises ten exons. The translation-initiation codon is located in exon 1, while the stop codon is found in the last exon (exon 10) .

Genetic studies have identified numerous polymorphisms within the DGCR2 gene region:

• 102 single-nucleotide polymorphisms (SNPs)

• 1 dinucleotide polymorphism

• 7 insertion/deletion polymorphisms

The human DGCR2 gene is located within the 22q11.2 region, which is subject to deletions associated with DiGeorge syndrome, velocardiofacial syndrome, and other developmental disorders collectively referred to as CATCH22 .

How does DGCR2 deficiency affect dendritic spine morphology and synaptic function?

DGCR2 deficiency significantly impacts dendritic spine formation and function. Knockdown of DGCR2 in hippocampal neurons results in a pronounced reduction in spine density. This morphological change corresponds with functional alterations in synaptic transmission, as demonstrated by several electrophysiological measures:

These findings indicate that DGCR2 deficiency specifically affects excitatory but not inhibitory synaptic transmission. The reduced miniature excitatory postsynaptic current (mEPSC) frequency with unchanged paired-pulse facilitation suggests that the deficit stems from reduced functional synapse number rather than altered presynaptic release probability .

For researchers investigating DGCR2 function, electrophysiological recordings in DGCR2-deficient neurons should focus on changes in spontaneous excitatory events and long-term synaptic plasticity measures, as these parameters show the most significant alterations.

What molecular mechanisms underlie DGCR2's role in synapse formation?

DGCR2 regulates synapse formation through a complex molecular mechanism involving transcellular interactions with presynaptic partners. The extracellular domain (ECD) of DGCR2 directly interacts with Neurexin1 (NRXN1), a presynaptic cell adhesion molecule .

This DGCR2-NRXN1 interaction serves multiple functions:

• It facilitates the binding between NRXN1 and Neuroligin1 (NLGN1), as demonstrated by co-immunoprecipitation assays showing increased NRXN1-NLGN1 binding when DGCR2 is present

• This facilitation occurs in a dose-dependent manner with respect to DGCR2 levels

• The effect requires the extracellular domain of DGCR2, as ΔECD mutants fail to enhance NRXN1-NLGN1 interaction

For experimental validation of these mechanisms, researchers should employ:

• Co-immunoprecipitation assays with tagged proteins (e.g., FLAG-hDGCR2)

• Domain deletion constructs (ΔECD, ΔICD) to map functional regions

• Competitive inhibition using soluble ECD to disrupt endogenous interactions

• Rescue experiments in DGCR2-knockdown neurons

Neutralizing the DGCR2-NRXN1 interaction using conditioned media containing soluble ECD fragments reduces spine density in hippocampal neurons, providing a valuable experimental approach for studying DGCR2 function in vitro .

How do mutations in DGCR2 contribute to behavioral abnormalities in mouse models?

DGCR2-deficient mice display a range of behavioral abnormalities that provide insights into the role of this protein in neural circuit function and behavior. These mice exhibit:

• Anxiety-like behaviors:

  • Reduced time spent in the central area of open field tests

  • Decreased entries and time spent in open arms of elevated plus maze

• Altered fear conditioning:

  • Impaired fear acquisition during training

  • Normal extinction and extinction test performance

• Sensorimotor gating:

  • Increased prepulse inhibition (PPI)

  • Slightly increased startle responses (not statistically significant)

These behavioral phenotypes correlate with the cellular and synaptic deficits observed in DGCR2-deficient mice, suggesting a causal relationship between DGCR2's role in synaptic function and its contributions to behavior.

For researchers conducting behavioral studies with DGCR2 mouse models, the most sensitive assays appear to be anxiety-related tests and fear conditioning acquisition phases. The behavioral test battery should include:

What is the relationship between DGCR2 and schizophrenia-related pathophysiology?

DGCR2 is located within the 22q11.2 deletion region associated with DiGeorge syndrome/velocardiofacial syndrome, which confers a high risk for developing schizophrenia. DGCR2 expression is reduced in individuals with schizophrenia, suggesting a potential role in disease pathophysiology .

Several lines of evidence connect DGCR2 dysfunction to schizophrenia-related mechanisms:

• Synaptic function: DGCR2 deficiency leads to reduced spine density and impaired glutamatergic transmission, aligning with the glutamate hypothesis of schizophrenia .

• Neural development: Knockdown of Dgcr2 in pyramidal neuron progenitors impacts the functional maturation of pyramidal neurons and interneurons in the medial prefrontal cortex (mPFC), a region implicated in schizophrenia .

• Circuit formation: DGCR2 influences the generation, migration, and integration of different neuronal subtypes in mPFC microcircuits, potentially contributing to schizophrenia vulnerability .

For researchers investigating DGCR2 in the context of schizophrenia, methodological approaches should include:

• Cell-type specific manipulations of DGCR2 expression in developmental models

• Electrophysiological assessment of excitatory/inhibitory balance in prefrontal circuits

• Analysis of dendritic spine morphology and density in schizophrenia-relevant brain regions

• Correlation of DGCR2 expression levels with positive, negative, and cognitive symptoms

What are the optimal conditions for producing and purifying recombinant mouse DGCR2/IDD protein?

For researchers working with recombinant mouse DGCR2/IDD protein, optimization of production and purification protocols is essential for obtaining functional protein. Based on the structural and functional characteristics of DGCR2, the following recommendations apply:

• Expression system selection:

  • Mammalian expression systems (HEK293 or CHO cells) are preferable for proper post-translational modifications, particularly glycosylation of the C-type lectin domain

  • Baculovirus-insect cell systems provide an alternative for higher yield while maintaining most post-translational modifications

• Construct design considerations:

  • Include a cleavable signal peptide for proper membrane insertion

  • Add affinity tags (His6 or FLAG) at the C-terminus to avoid interfering with the N-terminal domains

  • Consider producing soluble extracellular domain (ECD) constructs for interaction studies

  • For full-length protein, include the PDZ-binding motif (TVV) at the C-terminus to maintain PSD-95 interaction capability

• Purification strategy:

  • Two-step purification combining affinity chromatography with size exclusion chromatography

  • Detergent selection is critical for maintaining protein stability and function (e.g., DDM or CHAPS)

  • Include protease inhibitors throughout the purification process

  • Consider native purification conditions to preserve protein-protein interactions

• Functional validation:

  • Binding assays with recombinant NRXN1 to confirm interaction capability

  • Circular dichroism to verify proper folding

  • Glycosylation analysis to confirm post-translational modifications

How can researchers effectively knock down or knockout DGCR2 in experimental models?

Researchers have several options for manipulating DGCR2 expression in experimental models, each with specific advantages and limitations:

• RNA interference (RNAi):

  • Short hairpin RNA (shRNA) approaches have been validated for DGCR2 knockdown

  • The construct sh-540 has demonstrated effective knockdown of DGCR2 in hippocampal neurons

  • RNAi allows for spatial and temporal control when delivered via viral vectors

  • Limitation: incomplete knockdown and potential off-target effects

• CRISPR/Cas9 genome editing:

  • Enables complete knockout of DGCR2

  • Can be delivered via viral vectors or electroporation

  • Allows for generation of conditional knockout models using Cre-loxP systems

  • Can be used to introduce specific mutations or domain deletions

• Dominant-negative approaches:

  • Expression of the soluble extracellular domain (ECD) of DGCR2 can disrupt endogenous DGCR2-NRXN1 interactions

  • Collection of conditioned media from HEK293T cells expressing ECD provides a non-genetic approach to inhibit DGCR2 function

Validation of knockdown/knockout efficiency should include:

• Quantitative PCR for mRNA expression

• Western blotting for protein levels

• Immunocytochemistry to confirm cellular localization changes

• Functional assays such as spine density quantification to confirm biological effects

What imaging techniques are most effective for studying DGCR2's role in dendritic spine formation?

Optimal imaging approaches for investigating DGCR2's role in dendritic spine formation combine high-resolution visualization with functional assessment:

• Confocal microscopy:

  • Standard approach for spine density and morphology analysis

  • Transfection of neurons with GFP allows visualization of dendritic architecture

  • Co-immunostaining for DGCR2 and synaptic markers (PSD-95, Synapsin) enables localization studies

  • Resolution: ~200-250 nm laterally, limiting detailed spine morphology assessment

• Super-resolution microscopy:

  • Structured illumination microscopy (SIM) provides 2x improvement in resolution

  • Stimulated emission depletion (STED) microscopy allows visualization of spine neck width and fine structural details

  • Single-molecule localization microscopy (STORM/PALM) enables precise protein localization within spines

• Live imaging approaches:

  • Time-lapse confocal or two-photon microscopy to monitor spine dynamics

  • Fluorescence recovery after photobleaching (FRAP) to assess DGCR2 mobility at synapses

  • Optogenetic or chemogenetic manipulation combined with imaging to link activity with spine changes

• Correlative microscopy:

  • Combined fluorescence and electron microscopy to link molecular distribution with ultrastructural features

  • Array tomography for multi-protein localization studies in relation to DGCR2

Sample preparation recommendations:

• Sparsely transfected hippocampal cultures (DIV14-21) for optimal visualization

• Fixed tissue sections from DGCR2 mutant mice for in vivo spine analysis

• Immunogold labeling for electron microscopy studies of DGCR2 distribution

Analysis approaches should include:

• Automated spine detection and classification software

• Quantification of spine density, morphology, and size

• Colocalization analysis with synaptic markers

• Correlation of spine parameters with electrophysiological measurements

How can researchers investigate the DGCR2-NRXN1 interaction in cellular and biochemical assays?

The interaction between DGCR2 and NRXN1 represents a key mechanism underlying DGCR2's function in spine development. Several complementary approaches can be used to study this interaction:

• Biochemical interaction assays:

  • Co-immunoprecipitation using epitope-tagged proteins (FLAG-hDGCR2, NRXN1β) in heterologous expression systems

  • Pull-down assays with recombinant protein domains

  • Surface plasmon resonance or bio-layer interferometry to measure binding kinetics

  • ELISA-based binding assays for quantitative analysis

• Cell-based interaction studies:

  • Cell aggregation assays with cells expressing DGCR2 or NRXN1

  • Trans-synaptic biotinylation assays to detect proximity in intact neurons

  • Split-GFP complementation to visualize interaction sites

  • FRET/FLIM analysis to measure protein-protein interactions in living cells

• Functional validation approaches:

  • Competitive inhibition using soluble extracellular domain fragments

  • Structure-function analysis using domain deletion mutants (ΔECD, ΔICD)

  • Site-directed mutagenesis of key residues in binding interfaces

  • Rescue experiments in DGCR2-knockdown neurons with wild-type or mutant constructs

For analyzing the impact on NRXN1-NLGN1 interaction:

• Triple transfection experiments (NRXN1β, NLGN1, with/without DGCR2)

• Co-IP assays to measure NRXN1-NLGN1 binding efficiency

• Dose-dependent analysis with varying DGCR2 expression levels

• Domain deletion studies to map regions required for facilitation

These methodological approaches provide complementary information about the molecular mechanisms underlying DGCR2 function in synapse formation and can be adapted to various experimental systems depending on the specific research questions.

How can DGCR2 research contribute to understanding neurodevelopmental disorders?

DGCR2 research offers significant insights into neurodevelopmental disorders, particularly those associated with 22q11.2 deletion syndrome and schizophrenia:

• Mechanistic understanding:

  • DGCR2 deficiency provides a molecular link between genetic risk (22q11.2 deletion) and neural circuit dysfunction

  • The protein's role in spine development and glutamatergic transmission connects it to core pathophysiological processes in neurodevelopmental disorders

  • Behavioral phenotypes in DGCR2-deficient mice partially recapitulate features of human disorders

• Developmental trajectory analysis:

  • DGCR2 influences early neurodevelopmental processes in the medial prefrontal cortex

  • Cell-type specific effects on pyramidal neurons and interneurons may explain the complex phenotypes associated with 22q11.2 deletion syndrome

  • Temporal specificity of DGCR2 function provides insights into critical periods of vulnerability

• Integration with other risk genes:

  • DGCR2 function intersects with other schizophrenia risk genes, particularly those involved in synaptic organization

  • The DGCR2-NRXN1 interaction connects two distinct genetic risk pathways (22q11.2 deletion and NRXN1 mutations)

  • This convergence suggests common pathophysiological mechanisms despite diverse genetic etiologies

Researchers investigating DGCR2 in translational contexts should consider:

• Parallel studies in human-derived cellular models (iPSC neurons) and mouse models

• Investigation of gene-gene interactions between DGCR2 and other risk genes

• Analysis of DGCR2 function across different developmental timepoints

• Correlation of DGCR2 dysfunction with specific clinical endophenotypes

What are the considerations for using DGCR2 as a therapeutic target in psychiatric disorders?

DGCR2's involvement in synaptic function and psychiatric disorder risk makes it a potential therapeutic target, albeit with several important considerations:

• Target validation status:

  • Mouse model evidence supports DGCR2's role in anxiety-related behaviors and synaptic function

  • Human genetic evidence links DGCR2 to schizophrenia risk through 22q11.2 deletion

  • Expression studies show reduced DGCR2 levels in schizophrenia samples

  • Further validation in human cellular models and additional behavioral domains is needed

• Potential therapeutic strategies:

  • Enhancement of DGCR2 expression or function in haploinsufficient conditions

  • Modulation of downstream signaling pathways affected by DGCR2 deficiency

  • Targeting the DGCR2-NRXN1-NLGN1 interaction complex

  • Development of peptide mimetics based on functional domains of DGCR2

• Target accessibility and specificity:

  • As a transmembrane protein, DGCR2 presents challenges for small molecule development

  • The extracellular domain offers potential for antibody-based or protein therapeutic approaches

  • Specificity may be challenging due to structural similarities with other C-type lectin domain proteins

  • The PDZ-binding motif represents a potentially targetable intracellular interaction site

• Therapeutic window considerations:

  • Developmental timing of intervention may be critical given DGCR2's role in neurodevelopment

  • Adult intervention may have limited efficacy for developmental consequences

  • Potential for both beneficial and adverse effects given DGCR2's broad synaptic functions

  • Selective targeting of specific brain regions or circuits may be necessary

Researchers considering DGCR2 as a therapeutic target should implement:

• Conditional expression systems to evaluate timing-dependent effects

• Circuit-specific manipulation approaches

• Careful assessment of both therapeutic benefits and potential adverse effects

• Biomarker development for patient stratification (e.g., DGCR2 expression levels)

How should researchers optimize antibody selection for DGCR2/IDD detection in mouse tissues?

Selecting appropriate antibodies for DGCR2/IDD detection requires consideration of several technical aspects:

• Epitope selection considerations:

  • Antibodies against the extracellular domain may be affected by glycosylation

  • C-terminal epitopes might be masked by interactions with PDZ domain-containing proteins

  • Intracellular domain epitopes generally provide more consistent detection

  • Species-specific epitopes should be considered for cross-reactivity concerns

• Validation requirements:

  • Western blotting should show a band at the expected molecular weight (~60-65 kDa)

  • Absence or reduction of signal in DGCR2 knockout or knockdown samples

  • Immunofluorescence pattern consistent with postsynaptic localization

  • Absorption controls with immunizing peptide

  • Correlation between protein and mRNA expression patterns

• Application-specific recommendations:

  • For immunocytochemistry: fixation conditions significantly affect epitope accessibility

  • For Western blotting: sample preparation should account for membrane protein nature

  • For immunoprecipitation: antibodies recognizing native conformations are required

  • For super-resolution microscopy: consider secondary antibody selection carefully

• Protocol optimization:

  • Antigen retrieval methods for fixed tissue sections

  • Detergent selection for membrane protein solubilization

  • Blocking conditions to minimize background

  • Signal amplification approaches for low-abundance detection

Researchers should maintain updated documentation of antibody validation results and sharing this information with the research community to improve reproducibility across studies.

What are the critical controls for experiments investigating DGCR2 function in dendritic spine development?

Robust experimental design for DGCR2 functional studies requires several critical controls:

• Genetic manipulation controls:

  • Multiple shRNA sequences targeting different regions of DGCR2 mRNA

  • Non-targeting shRNA with similar GC content

  • Rescue experiments with shRNA-resistant DGCR2 constructs

  • Domain deletion controls (ΔECD, ΔICD) to establish structure-function relationships

• Cellular phenotype controls:

  • Analysis of multiple neuronal populations (hippocampal, cortical neurons)

  • Time-course analysis to distinguish developmental vs. maintenance effects

  • Assessment of both excitatory and inhibitory neurons

  • Quantification of multiple spine parameters (density, morphology, maturity)

• Biochemical interaction controls:

  • Protein expression level normalization

  • Reciprocal co-immunoprecipitation

  • Competition experiments with soluble domains

  • Negative control proteins with similar subcellular localization

• Functional outcome controls:

  • Parallel analysis of morphological and electrophysiological parameters

  • Assessment of both spontaneous and evoked synaptic activity

  • Analysis of both AMPA and NMDA receptor-mediated currents

  • Correlation of cellular phenotypes with behavioral outcomes

• Statistical considerations:

  • Appropriate sample sizes based on effect size estimation

  • Blinded analysis of morphological and functional outcomes

  • Hierarchical analysis accounting for multiple neurons from individual animals

  • Multiple comparison corrections for analysis of different parameters

Implementation of these controls ensures that experimental findings related to DGCR2 function are robust, specific, and reproducible across different laboratory settings.